November 19, 2025 — Leads & Copy — James Huang has been appointed as the Non-Executive Chairman of the Board of Directors at CASI Pharmaceuticals, Inc., effective November 17, 2025. Huang, a current independent board member, was unanimously voted into the position by the Board.
Dr. Wei-Wu He will step down from his role as Executive Chairman but will remain a member of the Board of Directors.
Huang, Founder and Managing Partner of Panacea Venture, previously held the position of Managing Partner at Kleiner Perkins (KPCB) China and Vivo Ventures. He brings over 35 years of experience building and investing in biopharma companies globally. Earlier in his career, Huang held senior roles in business development, sales & marketing, and research & development at Tularik Inc., GlaxoSmithKline LLC, Bristol-Myers Squibb and ALZA Corp.
Huang also serves on the board of directors of Kindstar Globalgene Technology, Inc., Connect Biopharma Holdings Limited, Lee’s Pharmaceutical Holdings Limited, Atara Biotherapeutics, Inc., and several private companies.
CASI Pharmaceuticals, Inc. is focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases. CID-103 has received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) in the U.S., with plans for the first patient in the first quarter of 2026. CASI is also recruiting patients in an ongoing Phase 1 study in immune thrombocytopenia (ITP) and assessing technologies for a stable, high concentration protein solution for subcutaneous injection.
David Cory, CEO of CASI, expressed confidence in Huang’s vision and alignment with company leadership as they prepare to capitalize and advance CID-103 in solid organ transplant rejection, starting with renal allograft antibody-mediated resistance or AMR.
CASI is involved in disputes and legal proceedings related to pipeline products, including EVOMELA® and CNCT-19. EVOMELA® and FOLOTYN® are proprietary to Acrotech Biopharma Inc. and its affiliates.
The company has cautioned readers not to place undue reliance on any forward-looking statements, as a number of factors could cause actual results to differ materially from those contained in any forward-looking statement.
Ingrid Choong, PhD, is the investor contact and can be reached at 650-619-6115 or ingridc@casipharmaceuticals.com.
Source: CASI Pharmaceuticals
